Drug Profile
Research programme: bifunctional chelators - Jubilant Life Sciences
Alternative Names: Bifunctional chelators research programme - Jubilant Life SciencesLatest Information Update: 20 Feb 2019
Price :
$50
*
At a glance
- Originator DRAXIS Specialty Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 05 Jan 2005 DRAXIS Pharma has merged with DRAXIMAGE to form DRAXIS Specialty Pharmaceuticals
- 06 Oct 2003 Preclinical trials in Cancer in Canada (unspecified route)